– USA, CA – Clarify Medical, Inc. today announced the appointment of John Schellhorn to its Board of Directors as President and CEO. The position had been filled by David F. Hale, the Board Chairman, who was named interim President and CEO in March. Mr. Hale will continue to serve as the Chairman of the Board.
Clarify Medical is the leading at-home, light therapy system for treating chronic skin conditions. Clarify Medical has developed a novel FDA-cleared device and software platform, the Clarify Medical Home Phototherapy System, to empower psoriasis, vitiligo, and eczema patients to better manage and deliver self-care. The Company is now poised for growth after closing an $18M Series A financing in October of last year. According to Mr. Hale “The Board is excited about the addition of Mr. Schellhorn because we believe he has the skills, experience, and track record to help accelerate the business.”
“I look forward to joining Clarify Medical at this important time in the company’s development,” said Mr. Schellhorn.
“The Clarify Medical System is particularly well-positioned to meet the needs of patients, providers, and payers as we continue to see a focus on shifting healthcare delivery from the clinic into the home. By enabling patients to self-administer therapy at home, controlled by their physician’s prescription via Clarify Medical’s cloud-connected technology and supported by Clarify Medical CarePartners throughout their treatment journey, physicians, patients and payers can finally utilize this cost-effective therapy modality as recommended by the recently published Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.” added John Schellhorn, “Clarify’s innovative system allows providers to appropriately control treatment dosage and patients to receive “always-on” care support by Clarify Medical CarePartners, who guide patients to drive treatment adherence, improve efficacy, and enhance long-term health outcomes.”
About John Schellhorn
John is a 35+ year veteran of the medical technology industry with extensive experience in the development and scaling of innovative healthcare technologies. He joined Global Kinetics Corporation in 2017 as President, CEO and Board Director to spearhead the company’s accelerated growth strategy to meet the demand for its lead product, the Personal KinetiGraph system. Before becoming President and CEO of GKC, he served as President and CEO of Monteris Medical Corporation where he oversaw development and commercialization of the world’s first MRI guided robotically controlled laser surgical system. Additionally, John helped raise $61M in equity financing and oversaw the doubling of sales annually between 2012-2015.
Previous to Monteris, John served as the Chief Commercialization Officer for BÂRRX Medical where he led a major expansion of US and International sales & marketing organizations, achieving greater than $40M annual revenue before its acquisition by Covidien for $430M. Following his time at BÂRRX, John served as President and CEO of Softscope Medical Technologies Inc., a clinical-stage, VC backed company in the GI space that was later acquired by Fujifilm Japan.
Earlier in his career, John held positions as P of Sales and Marketing for the Peripheral Vascular Division of ev3 Inc., VP and General Manager International for ACMI Corporation, and various sales and marketing positions, domestically and internationally, with Boston Scientific. Prior to his commercial career, he served for 7 years as a U.S. Marine Corps pilot.
About Clarify Medical, Inc.
Clarify Medical is a private San Diego-based medical device company focused on developing innovative technology, products and services that improve care for people with chronic skin conditions. Its Clarify Medical Home Phototherapy System is now available nationally in the U.S.
For more information: https://www.clarifymed.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
